Durability of Glycemic Control After Metformin Failure: Predictive Modelling From The DISCOVER programme (https://doi.org/10.1111/dom.13966)

DISCOVER is a multinational 3-yr prospective observational study of second-line glucose lowering therapies. In this study, the DISCOVER authors have developed and validated two prognostic models to evaluate the durability of glycemic control after initiating second-line therapy in patients failing on metformin. Durable control was defined as consecutive HbA1c levels ‘on target’ at 6, 12 and 24 months following second-line therapy initiation. These predictive models, which will be available to clinicians & use various clinical inputs, provide an estimation of the probability of achieving & maintaining glycemic control over 2-years following initiation of different second-line agents as add-on to metformin.